Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Carcinoid tumour
- Focus Therapeutic Use
Most Recent Events
- 23 Jan 2013 Biomarkers information updated
- 14 Aug 2007 Status changed from in progres to completed.
- 15 Aug 2005 New trial record.